Einloggen

Thematische Bibliographien / COMBINATORIAL THERAPY / Zeitschriftenartikel

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: COMBINATORIAL THERAPY.

Zeitschriftenartikel zum Thema „COMBINATORIAL THERAPY“

Autor: Grafiati

Veröffentlicht am 11. September 2023

Zuletzt aktualisiert am 25. Juli 2025

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "COMBINATORIAL THERAPY" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

Stritzker, J., and A. A. Szalay. "Single-agent combinatorial cancer therapy." Proceedings of the National Academy of Sciences 110, no. 21 (2013): 8325–26. http://dx.doi.org/10.1073/pnas.1305832110.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Baust, J. G. "Cryoablation: An Emergent Combinatorial Therapy." Cryobiology 92 (February 2020): 272. http://dx.doi.org/10.1016/j.cryobiol.2019.11.010.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Koh, Yoon Woo. "Combinatorial Targeted Therapy in Thyroid Cancer." Korean Journal of Otorhinolaryngology-Head and Neck Surgery 53, no. 4 (2010): 203. http://dx.doi.org/10.3342/kjorl-hns.2010.53.4.203.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Mittra, Arjun, and Debu Tripathy. "Looking ahead to rational combinatorial therapy." Community Oncology 9, no. 2 (2012): 40–41. http://dx.doi.org/10.1016/j.cmonc.2012.02.002.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Sabbatino, Francesco, Yangyang Wang, Ravin Poudel, et al. "Novel combinatorial therapy for pancreatic adenocarcinoma." Journal of the American College of Surgeons 217, no. 3 (2013): S137. http://dx.doi.org/10.1016/j.jamcollsurg.2013.07.319.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Anitha, A., S. Maya, Amal J. Sivaram, U. Mony, and R. Jayakumar. "Combinatorial nanomedicines for colon cancer therapy." Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 8, no. 1 (2015): 151–59. http://dx.doi.org/10.1002/wnan.1353.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Vojvodic, Sladjana, Gabor Katona, and Miroslav Sarac. "Combinatorial pharmacogenomic test for successful antidepressant treatment of a major depressive disorder." Medical review 74, no. 3-4 (2021): 117–22. http://dx.doi.org/10.2298/mpns2104117v.

Der volle Inhalt der Quelle

Annotation:

Introduction. The combinatorial pharmacogenomic test has shown the potential to predict antidepressant response, tolerability, selection, and dosage in the treatment of a major depressive disorder. A case of successful management of antidepressant therapy adjustment is reported by using the combinatorial pharmacogenomic test. Case Report. A 53-year old man, severely disabled due to a rare genetic disease, Usher syndrome type 3, was treated with numerous antidepressants. However, episodes of major depression recurred, along with frequent suicidal thoughts. A combinatorial pharmacogenomic test w

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Kushwah, Atar Singh, Rajnikant Mishra, Ashwin Kumar Shukla, and Monisha Banerjee. "Combinatorial therapy of Cynodon dactylon and Metformin with Cisplatin in cervical cancer." Journal of Scientific Research 66, no. 04 (2022): 35–41. http://dx.doi.org/10.37398/jsr.2022.660406.

Der volle Inhalt der Quelle

Annotation:

Cisplatin based chemoradiation (CRT) is the standard treatment for cervical cancer, which controls tumor growth and improves the overall survival of patients. However, patients undergoing chemo-radiation show widespread toxicities which may be either early or late. There is a constant effort to improve cancer therapy and overcome current challenges in cervical cancer by developing a combinatorial drug therapy using phytocompounds. In the present study, we review the combinatorial therapy of Cynodon dactylon and metformin with cisplatin as an alternative therapy for cervical cancer. During freq

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Sabei, Fahad Y., Olena Taratula, Hassan A. Albarqi, et al. "A targeted combinatorial therapy for Ewing's sarcoma." Nanomedicine: Nanotechnology, Biology and Medicine 37 (October 2021): 102446. http://dx.doi.org/10.1016/j.nano.2021.102446.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Kwong, L. N., and M. A. Davies. "Targeted therapy for melanoma: rational combinatorial approaches." Oncogene 33, no. 1 (2013): 1–9. http://dx.doi.org/10.1038/onc.2013.34.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

Mukerjee, A., A. P. Ranjan, and J. K. Vishwanatha. "Combinatorial Nanoparticles for Cancer Diagnosis and Therapy." Current Medicinal Chemistry 19, no. 22 (2012): 3714–21. http://dx.doi.org/10.2174/092986712801661176.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Bhatia, Karanpreet, Bhumika, and Asmita Das. "Combinatorial drug therapy in cancer - New insights." Life Sciences 258 (October 2020): 118134. http://dx.doi.org/10.1016/j.lfs.2020.118134.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

Beik, Jaber, Maziar Khateri, Zohreh Khosravi, et al. "Gold nanoparticles in combinatorial cancer therapy strategies." Coordination Chemistry Reviews 387 (May 2019): 299–324. http://dx.doi.org/10.1016/j.ccr.2019.02.025.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

Liu, Tingting, Bo Jin, Jun Chen, et al. "Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis." Therapeutic Advances in Medical Oncology 12 (January 2020): 175883592094092. http://dx.doi.org/10.1177/1758835920940927.

Der volle Inhalt der Quelle

Annotation:

Background: This network meta-analysis assessed the comparative risk of grade 3–5 and grade 5 treatment-related adverse events (TRAEs) for immune checkpoint inhibitors (ICIs), either alone or in combination with other modalities, for cancer treatment. Methods: PubMed, Embase, Cochrane Library, Web of Science, and recent predominant oncology congresses were searched for relevant phase II and phase III randomized controlled trials (RCTs). As outcomes, grade 3–5, and grade 5 TRAE outcomes were reported as odds ratios and 95% confidence intervals. Results: In 67 RCTs involving 36,422 patients and

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

Wang, Bin, Jin Huang, Shanshan Li, et al. "The Combinatorial Effect of Cisplatin and Moxibustion on Tumor Growth Inhibition with Special Reference to Modulation of the Immune Microenvironment in Lewis Lung Cancer Mice." Evidence-Based Complementary and Alternative Medicine 2020 (December 29, 2020): 1–14. http://dx.doi.org/10.1155/2020/3170803.

Der volle Inhalt der Quelle

Annotation:

Objective. As a first-line treatment for non-small cell lung cancer (NSCLC), the efficacy of chemotherapy is still unsatisfactory. Moxibustion has been shown to improve the side effects of radiotherapy and chemotherapy and regulate immune function. This study aimed to explore the antitumor effects and potential mechanisms of combinatorial cisplatin and moxibustion treatment for NSCLC by targeting the tumor microenvironment. Methods. Lewis lung cancer (LLC)-bearing mice were induced and treated with cisplatin or/and moxibustion at ST36 (Zusanli), and the growth, weight, and area of the tumor we

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

León-Buitimea, Angel, Cesar R. Garza-Cárdenas, María Fernanda Román-García, César Agustín Ramírez-Díaz, Martha Ulloa-Ramírez, and José Rubén Morones-Ramírez. "Nanomaterials-Based Combinatorial Therapy as a Strategy to Combat Antibiotic Resistance." Antibiotics 11, no. 6 (2022): 794. http://dx.doi.org/10.3390/antibiotics11060794.

Der volle Inhalt der Quelle

Annotation:

Since the discovery of antibiotics, humanity has been able to cope with the battle against bacterial infections. However, the inappropriate use of antibiotics, the lack of innovation in therapeutic agents, and other factors have allowed the emergence of new bacterial strains resistant to multiple antibiotic treatments, causing a crisis in the health sector. Furthermore, the World Health Organization has listed a series of pathogens (ESKAPE group) that have acquired new and varied resistance to different antibiotics families. Therefore, the scientific community has prioritized designing and dev

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

Seo, Hyun Ah, Sokviseth Moeng, Seokmin Sim, Hyo Jeong Kuh, Soo Young Choi, and Jong Kook Park. "MicroRNA-Based Combinatorial Cancer Therapy: Effects of MicroRNAs on the Efficacy of Anti-Cancer Therapies." Cells 9, no. 1 (2019): 29. http://dx.doi.org/10.3390/cells9010029.

Der volle Inhalt der Quelle

Annotation:

The susceptibility of cancer cells to different types of treatments can be restricted by intrinsic and acquired therapeutic resistance, leading to the failure of cancer regression and remission. To overcome this problem, a combination therapy has been proposed as a fundamental strategy to improve therapeutic responses; however, resistance is still unavoidable. MicroRNA (miRNAs) are associated with cancer therapeutic resistance. The modulation of dysregulated miRNA levels through miRNA-based therapy comprising a replacement or inhibition approach has been proposed to sensitize cancer cells to o

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

Singh, P., A. Uzgare, I. Litvinov, S. R. Denmeade, and J. T. Isaacs. "Combinatorial androgen receptor targeted therapy for prostate cancer." Endocrine-Related Cancer 13, no. 3 (2006): 653–66. http://dx.doi.org/10.1677/erc.1.00797.

Der volle Inhalt der Quelle

Annotation:

Prostatic carcinogenesis is associated with changes in the androgen receptor (AR) axis converting it from a paracrine dependence upon stromal signaling to an autocrine-initiated signaling for proliferation and survival of prostatic cancer cells. This malignant conversion is due to gain of function changes in which the AR activates novel genomic (i.e. transcriptional) and non-genomic signaling pathways, which are not present in normal prostate epithelial cells. During further progression, additional molecular changes occur which allow these unique malignancy-dependent AR signaling pathways to b

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

Vivero-Escoto, Juan L. "Multifunctional Polysilsesquioxane Nanoparticles for Combinatorial Therapy of Cancer." Video Proceedings of Advanced Materials 1, no. 1 (2020): 2020–0829. http://dx.doi.org/10.5185/vpoam.2020.0829.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

Kanda, Akio, Satoru Ebihara, Hiroyasu Yasuda, Ohrui Takashi, Takahiko Sasaki, and Hidetada Sasaki. "A Combinatorial Therapy for Pneumonia in Elderly People." Journal of the American Geriatrics Society 52, no. 5 (2004): 846–47. http://dx.doi.org/10.1111/j.1532-5415.2004.52230_5.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

Jernberg-Wiklund, Helena, and Kenneth Nilsson. "Toward a rational combinaTORial therapy for multiple myeloma." Blood 104, no. 13 (2004): 3845–46. http://dx.doi.org/10.1182/blood-2004-09-3648.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

Gálvez-Gastélum, F. J., J. J. Garcia-Bañuelos, C. Beas-Zárate, et al. "Combinatorial gene therapy induces regression of hepatic encephalopathy." Gene Therapy 18, no. 1 (2010): 88–94. http://dx.doi.org/10.1038/gt.2010.107.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

Pang, Kaifang, Ying-Wooi Wan, William T. Choi, et al. "Combinatorial therapy discovery using mixed integer linear programming." Bioinformatics 30, no. 10 (2014): 1456–63. http://dx.doi.org/10.1093/bioinformatics/btu046.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Jiang, Kai, Di Zhao, Rui Ye, et al. "Transdermal delivery of poly-hyaluronic acid-based spherical nucleic acids for chemogene therapy." Nanoscale 14, no. 5 (2022): 1834–46. http://dx.doi.org/10.1039/d1nr06353g.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

Takaichi, Shohei, Jennifer L. Tomlinson, Mincheng Yu, et al. "Effect of AXL on cholangiocarcinoma survival and sensitivity to cytotoxic chemotherapy." Journal of Clinical Oncology 41, no. 4_suppl (2023): 591. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.591.

Der volle Inhalt der Quelle

Annotation:

591 Background: Cholangiocarcinoma (CCA) is a lethal disease with limited therapeutic options. We have demonstrated the interaction of Src-family kinase LCK with AXL, a TAM receptor tyrosine kinase (RTK), by phosphoproteomic analysis in CCA ( J Hepatol 2022). AXL is reported to act as a mechanism of acquired drug resistance in solid cancers. However, the role of AXL in CCA remains to be elucidated. Here, we investigated the significance of AXL expression as a potential therapeutic target in CCA. Methods: We first evaluated the expression levels of AXL in CCA and the associations with patient o

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

Bao, Xuhui, Stephen T. Keir, Smita K. Nair, Ira Pastan, Darell D. Bigner, and Vidyalakshmi Chandramohan. "A combinatorial immunotherapy for malignant brain tumors: D2C7 immunotoxin and immune checkpoint inhibitors." Journal of Clinical Oncology 35, no. 7_suppl (2017): 102. http://dx.doi.org/10.1200/jco.2017.35.7_suppl.102.

Der volle Inhalt der Quelle

Annotation:

102 Background: Immunotoxins can induce direct and rapid cytotoxicity by targeting specific tumor antigens. D2C7 is a unique recombinant immunotoxin targeting EGFRwt/EGFRvIII, two frequently overexpressed proteins on gliomas, and is currently being tested in a phase I/II clinical trial (NCT02303678) for recurrent malignant gliomas. Immunotoxins have also been shown to induce a secondary antitumor immune response via stimulation of cytotoxic T lymphocytes (CTLs). Immune checkpoint inhibitors, which have successfully treated several advanced tumors by promoting the antitumor function of CTLs, ma

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

Ahmad, Touqeer, Rizwana Sarwar, Ayesha Iqbal, et al. "Recent advances in combinatorial cancer therapy via multifunctionalized gold nanoparticles." Nanomedicine 15, no. 12 (2020): 1221–37. http://dx.doi.org/10.2217/nnm-2020-0051.

Der volle Inhalt der Quelle

Annotation:

The diverse behavior of nanogold in the therapeutic field is related to its unique size and shape. Nanogold offers improvements in modern diagnostic and therapeutic implications, increases disease specificity and targeted drug delivery, and is relatively economical compared with other chemotherapeutic protocols. The diagnosis of cancer and photothermal therapy improve drastically with the implementation of nanotechnology. Different types of nanoparticles, that is, gold silica nanoshells, nanorods and nanospheres of diverse shapes and geometries, are used widely in the photothermal therapy of c

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Wang, Mu-En, Wei-Ling Tu, Yi Lu, et al. "Abstract 948: A novel combinatorial therapy for lethal neuroendocrine prostate cancer." Cancer Research 84, no. 6_Supplement (2024): 948. http://dx.doi.org/10.1158/1538-7445.am2024-948.

Der volle Inhalt der Quelle

Annotation:

Abstract Background: Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer that can arise de novo, but more commonly develops after hormone therapies for advanced prostate adenocarcinoma. Current treatment options for NEPC are only palliative, and most patients die within several months. Additionally, single-agent clinical trials targeting NEPC so far have only produced disappointing results, highlighting the clear need to develop effective combinatorial therapies for NEPC. RB1 loss, a pivotal event in the development of NEPC, can sensitize cancer cells to fer

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

Egorova, Anna, Ivan Pyankov, Marianna Maretina, Vladislav Baranov, and Anton Kiselev. "Peptide Nanoparticle-Mediated Combinatorial Delivery of Cancer-Related siRNAs for Synergistic Anti-Proliferative Activity in Triple Negative Breast Cancer Cells." Pharmaceuticals 14, no. 10 (2021): 957. http://dx.doi.org/10.3390/ph14100957.

Der volle Inhalt der Quelle

Annotation:

Triple negative breast cancer (TNBC) is one of the deadliest types of cancer for women of different age groups. Frequently this cancer does not respond to conservative treatment. Combinatorial RNAi can be suggested as an advanced approach to TNBC therapy. Due to the fact that TNBC cells overexpress chemokine receptor 4 we used modular L1 peptide-based nanoparticles modified with CXCR4 ligand for combinatorial delivery of siRNAs suppressing major transduction pathways. TNBC cell line MDA-MB-231 was used as a cellular model. Genes encoding the AQP3, CDC20, and COL4A2 proteins responsible for pro

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

Kumari, Smita, Dia Advani, Sudhanshu Sharma, Rashmi K. Ambasta, and Pravir Kumar. "Combinatorial therapy in tumor microenvironment: Where do we stand?" Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1876, no. 2 (2021): 188585. http://dx.doi.org/10.1016/j.bbcan.2021.188585.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

Hao, Yang, Chih Kit Chung, Zhenfeng Yu, et al. "Combinatorial Therapeutic Approaches with Nanomaterial-Based Photodynamic Cancer Therapy." Pharmaceutics 14, no. 1 (2022): 120. http://dx.doi.org/10.3390/pharmaceutics14010120.

Der volle Inhalt der Quelle

Annotation:

Photodynamic therapy (PDT), in which a light source is used in combination with a photosensitizer to induce local cell death, has shown great promise in therapeutically targeting primary tumors with negligible toxicity and minimal invasiveness. However, numerous studies have shown that noninvasive PDT alone is not sufficient to completely ablate tumors in deep tissues, due to its inherent shortcomings. Therefore, depending on the characteristics and type of tumor, PDT can be combined with surgery, radiotherapy, immunomodulators, chemotherapy, and/or targeted therapy, preferably in a patient-ta

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

Cortese, Barbara, Stefania D’Amone, Mariangela Testini, Patrizia Ratano, and Ilaria Elena Palamà. "Hybrid Clustered Nanoparticles for Chemo-Antibacterial Combinatorial Cancer Therapy." Cancers 11, no. 9 (2019): 1338. http://dx.doi.org/10.3390/cancers11091338.

Der volle Inhalt der Quelle

Annotation:

Background: A great number of therapeutic limitations, such as chemoresistance, high dosage, and long treatments, are still present in cancer therapy, and are often followed by side effects such as infections, which represent the primary cause of death among patients. Methods: We report pH- and enzymatic-responsive hybrid clustered nanoparticles (HC-NPs), composed of a PCL polymeric core loaded with an anticancer drug, such as Imatinib Mesylate (IM), and coated with biodegradable multilayers embedded with antibacterial and anticancer baby-ship silver NPs, as well as a monoclonal antibody for s

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

Singh, Abhay Kumar, Baidyanath Chakravarty, and Koel Chaudhury. "Nanoparticle-Assisted Combinatorial Therapy for Effective Treatment of Endometriosis." Journal of Biomedical Nanotechnology 11, no. 5 (2015): 789–804. http://dx.doi.org/10.1166/jbn.2015.2020.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

Matthews, Ruth C., and James P. Burnie. "Recombinant antibodies: a natural partner in combinatorial antifungal therapy." Vaccine 22, no. 7 (2004): 865–71. http://dx.doi.org/10.1016/j.vaccine.2003.11.032.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

Shanavas, Asifkhan, Nishant K. Jain, Navneet Kaur, et al. "Polymeric Core–Shell Combinatorial Nanomedicine for Synergistic Anticancer Therapy." ACS Omega 4, no. 22 (2019): 19614–22. http://dx.doi.org/10.1021/acsomega.9b02167.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

Gálvez-Gastélum, Francisco J., Aida A. Segura-Flores, María D. Senties-Gomez, Jose F. Muñoz-Valle, and Juan S. Armendáriz-Borunda. "Combinatorial gene therapy renders increased survival in cirrhotic rats." Journal of Biomedical Science 17, no. 1 (2010): 42. http://dx.doi.org/10.1186/1423-0127-17-42.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

Li, V. W., R. A. Ball, N. Vasan, and W. W. Li. "Antiangiogenic therapy for squamous cell carcinoma using combinatorial agents." Journal of Clinical Oncology 23, no. 16_suppl (2005): 3032. http://dx.doi.org/10.1200/jco.2005.23.16_suppl.3032.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

Barbosa, Silvia, Antonio Topete, Manuel Alatorre-Meda, et al. "Targeted Combinatorial Therapy Using Gold Nanostars as Theranostic Platforms." Journal of Physical Chemistry C 118, no. 45 (2014): 26313–23. http://dx.doi.org/10.1021/jp505979e.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

Tojjari, Alireza, James Yu, and Anwaar Saeed. "Immunotherapy and Radiation Therapy Combinatorial Approaches in Hepatocellular Carcinoma." Cancers 16, no. 5 (2024): 1058. http://dx.doi.org/10.3390/cancers16051058.

Der volle Inhalt der Quelle

Annotation:

Hepatocellular carcinoma (HCC), a prevalent and often fatal liver cancer, presents significant treatment challenges, especially in its advanced stages. This article delves into the promising approach of combining immunotherapy, particularly immune checkpoint inhibitors, with radiation therapy, a cornerstone of HCC management. Our review synthesizes current preclinical and clinical research, highlighting the potential synergistic effects of this combinational treatment. Emerging evidence suggests that this synergy enhances tumor control and improves patient survival rates. The combination lever

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

Venkatesh, Yarra, Kumari Shanti Kiran, Sk Sheriff Shah, Amrita Chaudhuri, Satyahari Dey, and N. D. Pradeep Singh. "One- and two-photon responsive sulfur dioxide (SO2) donors: a combinatorial drug delivery for improved antibiotic therapy." Organic & Biomolecular Chemistry 17, no. 10 (2019): 2640–45. http://dx.doi.org/10.1039/c9ob00090a.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

Wei, Lan, Jiaru Zhu, Qi Wang, et al. "Injectable thermosensitive hydrogel co-loading with ATRi and doxorubicin for the treatment of triple-negative breast cancer." RSC Advances 15, no. 26 (2025): 20385–96. https://doi.org/10.1039/d5ra03120f.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

Ying, Poi Liu, and Berkhout Ben. "Combinatorial RNAi strategies against HIV-1 and other escape-prone viruses." International Journal of BioSciences and Technology (IJBST) ISSN: 0974-3987 1, no. 2 (2008): 1–10. https://doi.org/10.5281/zenodo.1422389.

Der volle Inhalt der Quelle

Annotation:

<strong>Abstract:  </strong>   RNA interference (RNAi) is an evolutionarily conserved mechanism in which double-stranded RNA (dsRNA) induces sequence-specific gene silencing. RNAi as a gene suppression tool holds great promise for basic research and multiple applications. RNAi strategies with a single inhibitor have received much attention and some are currently being tested in clinical trials as potential drug for infectious diseases, cancer and genetic disorders. Although very successful, such an RNAi mono-therapy is not always sufficient. For example, several proteins should be si

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

Wu, Zhen, Ruiping Gao, Hong Li, et al. "New insight into the joint significance of dietary jujube polysaccharides and 6-gingerol in antioxidant and antitumor activities." RSC Advances 11, no. 53 (2021): 33219–34. http://dx.doi.org/10.1039/d1ra03640h.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

Lin, Xiao, Yanbin Cao, Jiong Li, et al. "Folic acid-modified Prussian blue/polydopamine nanoparticles as an MRI agent for use in targeted chemo/photothermal therapy." Biomaterials Science 7, no. 7 (2019): 2996–3006. http://dx.doi.org/10.1039/c9bm00276f.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

Singh, Amit, Meghna Talekar, Thanh-Huyen Tran, Abishek Samanta, Ravi Sundaram, and Mansoor Amiji. "Combinatorial approach in the design of multifunctional polymeric nano-delivery systems for cancer therapy." J. Mater. Chem. B 2, no. 46 (2014): 8069–84. http://dx.doi.org/10.1039/c4tb01083c.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

46

Wang, Yidan, Xiaojuan Pang, Jinping Wang, et al. "Magnetically-targeted and near infrared fluorescence/magnetic resonance/photoacoustic imaging-guided combinational anti-tumor phototherapy based on polydopamine-capped magnetic Prussian blue nanoparticles." Journal of Materials Chemistry B 6, no. 16 (2018): 2460–73. http://dx.doi.org/10.1039/c8tb00483h.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

47

Cao, Dongling, Jinlin He, Jiaying Xu, et al. "Polymeric prodrugs conjugated with reduction-sensitive dextran–camptothecin and pH-responsive dextran–doxorubicin: an effective combinatorial drug delivery platform for cancer therapy." Polymer Chemistry 7, no. 25 (2016): 4198–212. http://dx.doi.org/10.1039/c6py00701e.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

48

Zhao, Chong, Hongxiang Liu, Sijun Huang, Yi Guo, and Li Xu. "Metal–Organic Framework-Capped Gold Nanorod Hybrids for Combinatorial Cancer Therapy." Molecules 29, no. 10 (2024): 2384. http://dx.doi.org/10.3390/molecules29102384.

Der volle Inhalt der Quelle

Annotation:

Recently, nanomaterials have attracted extensive attention in cancer-targeting therapy and as drug delivery vehicles owing to their unique surface and size properties. Multifunctional combinations of nanomaterials have become a research hotspot as researchers aim to provide a full understanding of their nanomaterial characteristics. In this study, metal–organic framework-capped gold nanorod hybrids were synthesized. Our research explored their ability to kill tumor cells by locally increasing the temperature via photothermal conclusion. The specific peroxidase-like activity endows the hybrids

APA, Harvard, Vancouver, ISO und andere Zitierweisen

49

Misra, S. K., X. Wang, I. Srivastava, et al. "Combinatorial therapy for triple negative breast cancer using hyperstar polymer-based nanoparticles." Chemical Communications 51, no. 93 (2015): 16710–13. http://dx.doi.org/10.1039/c5cc07709e.

Der volle Inhalt der Quelle

Annotation:

We report the ability of a novel combinatorial therapy obtained from nanoparticles of hyperstar polymers encompassing drugs to selectively target triple negative breast cancer (TNBC) cell proliferation through STAT3 and topoisomerase-II pathways.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

50

Guha, Sujay, Neal D. Mathew, Chigoziri Konkwo, et al. "Combinatorial glucose, nicotinic acid and N-acetylcysteine therapy has synergistic effect in preclinical C. elegans and zebrafish models of mitochondrial complex I disease." Human Molecular Genetics 30, no. 7 (2021): 536–51. http://dx.doi.org/10.1093/hmg/ddab059.

Der volle Inhalt der Quelle

Annotation:

Abstract Mitochondrial respiratory chain disorders are empirically managed with variable antioxidant, cofactor and vitamin ‘cocktails’. However, clinical trial validated and approved compounds, or doses, do not exist for any single or combinatorial mitochondrial disease therapy. Here, we sought to pre-clinically evaluate whether rationally designed mitochondrial medicine combinatorial regimens might synergistically improve survival, health and physiology in translational animal models of respiratory chain complex I disease. Having previously demonstrated that gas-1(fc21) complex I subunit nduf

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!